Primecap Management Co. CA Sells 40,000 Shares of Nurix Therapeutics, Inc. $NRIX

Primecap Management Co. CA decreased its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 19.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 170,000 shares of the company’s stock after selling 40,000 shares during the period. Primecap Management Co. CA owned about 0.22% of Nurix Therapeutics worth $1,571,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in NRIX. Patient Square Capital LP lifted its holdings in shares of Nurix Therapeutics by 6.0% during the 3rd quarter. Patient Square Capital LP now owns 437,237 shares of the company’s stock worth $4,040,000 after acquiring an additional 24,941 shares during the last quarter. Vanguard Group Inc. lifted its stake in Nurix Therapeutics by 0.5% during the third quarter. Vanguard Group Inc. now owns 4,488,776 shares of the company’s stock worth $41,476,000 after purchasing an additional 23,269 shares during the last quarter. Profund Advisors LLC lifted its stake in Nurix Therapeutics by 24.5% during the third quarter. Profund Advisors LLC now owns 20,455 shares of the company’s stock worth $189,000 after purchasing an additional 4,022 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in shares of Nurix Therapeutics by 61.9% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 42,759 shares of the company’s stock worth $395,000 after purchasing an additional 16,353 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Nurix Therapeutics during the 3rd quarter valued at about $510,000.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NRIX. BTIG Research restated a “buy” rating and issued a $30.00 target price on shares of Nurix Therapeutics in a research report on Thursday, January 29th. Royal Bank Of Canada lifted their price target on shares of Nurix Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Truist Financial assumed coverage on shares of Nurix Therapeutics in a research note on Monday, November 24th. They issued a “buy” rating and a $30.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Thursday, January 22nd. Finally, Piper Sandler boosted their price target on shares of Nurix Therapeutics from $32.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $29.50.

Insider Transactions at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 4,895 shares of the business’s stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $81,257.00. Following the transaction, the insider owned 83,672 shares in the company, valued at $1,388,955.20. The trade was a 5.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Houte Hans Van sold 3,661 shares of the stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $60,772.60. Following the completion of the sale, the chief financial officer owned 45,427 shares of the company’s stock, valued at approximately $754,088.20. This trade represents a 7.46% decrease in their position. The SEC filing for this sale provides additional information. 7.40% of the stock is owned by insiders.

Nurix Therapeutics Stock Down 0.9%

Shares of NASDAQ NRIX opened at $15.97 on Friday. The firm’s fifty day moving average is $17.65 and its 200 day moving average is $14.03. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $22.50. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -5.25 and a beta of 1.96.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Wednesday, January 28th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. The business had revenue of $13.58 million for the quarter, compared to analyst estimates of $13.41 million. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. Equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.